Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
Lymphoma, Follicular
|
|
0.010 |
GeneticVariation
|
BEFREE |
Comparative whole exome sequencing was then performed, which identified a KRAS p.G13D mutation in the LCS that was not present in the FL.
|
30322385 |
2018 |
Squamous cell carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS
|
|
0.010 |
GeneticVariation
|
BEFREE |
Both diseases were proposed to represent mosaic disorders, but only very recently whole-genome sequencing has led to the identification of somatic KRAS mutations, p.Leu19Phe and p.Gly13Asp, in affected tissue from two individuals with OES.
|
26970110 |
2016 |
Tumour budding
|
|
0.010 |
GeneticVariation
|
BEFREE |
KRas G12V primary tumors had lower apoptosis (7.0 ± 1.2 vs. 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs. 0.6 ± 0.1, P = 0.04), and a higher percentage of C-X-C chemokine receptor type 4 (CXCR4)-overexpressing intravasated tumor emboli (49.8 ± 9.4% vs. 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors.
|
25359494 |
2015 |
Sezary Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
Lymphoma, T-Cell, Cutaneous
|
|
0.010 |
GeneticVariation
|
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
Mycosis Fungoides
|
|
0.010 |
GeneticVariation
|
BEFREE |
One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change.
|
21209378 |
2011 |
Refractory Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors.
|
20978259 |
2010 |
Secondary Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses.
|
19679400 |
2009 |
Thymoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
Autoimmune Lymphoproliferative Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
Hematologic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
Hypoglycemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Target sequencing analysis revealed, both in primary tumor and metastasis, a pathogenic KRAS gene missense mutation c.38G > A p.(Gly13Asp) and a likely pathogenic CTNNB1 gene missense mutation c.94G > A p.(Asp32Asn).
|
31823050 |
2020 |
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation.
|
27573925 |
2016 |
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We report here two cases of ALK-rearranged adenocarcinomas harboring concomitant exon 2 K-RAS mutations (G13D and Q61H).
|
26898615 |
2016 |
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses.
|
19679400 |
2009 |
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
|
30896620 |
2019 |
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells.
|
30226622 |
2018 |
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations.
|
29498789 |
2018 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |